German specialty chemicals producer Lanxess completed the sale of its 40% stake in chemical park operator Currenta to Australia’s Macquarie Infrastructure and Real Assets (MIRA) at the end of April. The sale agreement was concluded in August 2019.
Tokyo, Japan-based Mitsubishi Chemical Corporation (MCC), through its US subsidiary acquires US chemicals and materials group Gelest from New Mountain Capital.
After more than seven years of collaboration, Syngenta and Novozymes are now entering the commercialization phase of their microbial-based foliar fungicide Taegro.
Seqens, a French provider of pharmaceutical synthesis and specialty ingredients, is planning to invest an undisclosed sum in a second isopropanol (IPA) production plant at Roussillon.
BASF has retracted its earnings estimate for 2020 communicated at the end of February, citing a clouded outlook amid the coronavirus pandemic. “In any case, the Feb. 28 forecast will not be met,” it said.
Evotec has formed a strategic partnership with Leon-Nanodrugs, a German-based provider of nanotechnology for the pharmaceutical industry.
Bayer has set aside €480 million to defend lawsuits brought by people who claim that Monsanto’s glyphosate-based herbicide Roundup caused their non-Hodgkins lymphoma, CEO Werner Baumann said at the company’s annual general meeting on Apr. 28.
Sanofi has urged the EU to create an equivalent of the US government’s Biomedical Advanced Research and Development Authority (BARDA) to coordinate research into a Covid-19 vaccine, or face being left behind.
US-based plastics, latex binders and synthetic rubber producer Trinseo is once again changing its leadership team as it implements a flatter organization to streamline decision making.
Plastics manufacturer Sekisui Chemical and the Innovation Network Corporation of Japan (INCJ) have formed a joint venture to verify and commercialize combustible waste-to-ethanol technology.
Ineos has joined forces with Plastic Energy to help promote and employ chemical recycling.
Paul-Ehrlich-Institut (PEI), Germany’s federal institute for vaccines and biomedicines, has given the go-ahead for Germany’s first clinical trial of a vaccine candidate to prevent COVID-19.
